| Harmony Bio and Inhibrx Raise Combined $247M in Public Market Debuts | Sarah de Crescenzo | 08/20/20 | National |
| Patient Death in Poseida Prostate Cancer Study Prompts Clinical Hold | Sarah de Crescenzo | 08/18/20 | San Diego |
| GlaxoSmithKline Multiple Myeloma Drug Earns FDA’s First Anti-BCMA Nod | Sarah de Crescenzo | 08/06/20 | National |
| Amid Boom Days for Biotech, Inhibrx Lines Up Another IPO Effort | Sarah de Crescenzo | 07/29/20 | San Diego |
| 3 Biotech IPOs Together Rake In Over a Half Billion to Advance Treatments | Sarah de Crescenzo | 07/13/20 | National |
| On Heels of $100M Financing, Annexon Bio Aims to Tack On More Via IPO | Sarah de Crescenzo | 07/06/20 | San Francisco |
| Relay Lays $200M IPO Plan to Fund Tests of Protein Motion Cancer Drugs | Sarah de Crescenzo | 06/25/20 | Boston |
| Sarepta Inks Codiak Deal to Explore Combining Exosomes, Muscle Meds | Sarah de Crescenzo | 06/22/20 | Boston |
| Bio Roundup: A Royal IPO, Akili Arrives, Orca Bio Surfaces & More | Frank Vinluan | 06/19/20 | National |
| AbbVie Commits $750M to Genmab Bispecific Antibody Cancer Drug Deal | Sarah de Crescenzo | 06/10/20 | National |
| After Inking Bristol Myers Pact, Repare Therapeutics Sets Sights on IPO | Frank Vinluan | 05/29/20 | Boston |
| Bio Roundup: ASCO Opens, Merck Takes On COVID, Evofem’s Approval & More | Sarah de Crescenzo | 05/29/20 | National |
| Applied Molecular Plots IPO to Back Transport of Biologic Drugs to Gut | Frank Vinluan | 05/20/20 | San Francisco |
| ADC’s $233M IPO Brings It to NYSE With Cancer Drug Launch on Horizon | Frank Vinluan | 05/15/20 | New York |
| Bio Roundup: FDA Dings BMS, Genfit’s Fall, Alexion’s Activist & More | Sarah de Crescenzo | 05/15/20 | National |
| From Overseas, Legend Biotech and Calliditas Therapeutics Eye the Nasdaq | Frank Vinluan | 05/15/20 | New York |
| Ayala’s IPO Raises $55M to Test Two Former Bristol Myers Cancer Drugs | Frank Vinluan | 05/08/20 | National |
| Lyra Therapeutics IPO Raises $56M for Tests of Tech for Runny Noses | Frank Vinluan | 05/01/20 | Boston |
| Bio Roundup: Remdesivir Data, Erasca’s $200M, a New FDA Nod & More | Sarah de Crescenzo | 05/01/20 | National |
| ADC Therapeutics Resubmits IPO to Fuel Cancer Drug Filing, Launch Plans | Frank Vinluan | 04/27/20 | New York |
| Bio Roundup: Fast FDA Approvals, Biogen Delays, ORIC’s IPO & More | Frank Vinluan | 04/24/20 | National |
| ORIC Pharma Gets $120M in IPO to Advance Drug-Resistant Cancer Therapies | Sarah de Crescenzo | 04/24/20 | San Francisco |
| Lantern Pharma IPO File Illuminates Plan to “Rescue” Failed Cancer Drugs | Frank Vinluan | 04/17/20 | Texas |
| Biotech Roundup: GSK’s Ante, Shakeup at Sage, Telehealth’s Rise & More | Frank Vinluan | 04/10/20 | National |
| Keros Therapeutics Raises $96M in Upsized IPO to Fuel Clinical Tests | Sarah de Crescenzo | 04/08/20 | Boston |
| Zentalis Upsizes IPO, Raising $165M for Cancer Drug Clinical Trials | Frank Vinluan | 04/03/20 | New York |
| Bio Roundup: Clinical Trials Paused, New MS Drug, Kallyope’s Cash & More | Frank Vinluan | 03/27/20 | National |
| Investors Shaken by Coronavirus Sow Seeds of M&A, Financing Slowdown | Sarah de Crescenzo | 03/23/20 | National |
| Keros Outlines IPO Plans Amid Markets Rocked by Coronavirus Pandemic | Sarah de Crescenzo | 03/23/20 | Boston |
| Bio Roundup: Pandemic Declared, Rubius Restarts, Kymera’s Cash & More | Frank Vinluan | 03/13/20 | National |
